Home  »  Morning Brief   »  How Did The Aravive (ARAV) Stock Rise 4% After-Hou...

How Did The Aravive (ARAV) Stock Rise 4% After-Hours?

On Monday, Aravive Inc. (Nasdaq: ARAV) advanced 4.55% to $0.83 after achieving a significant milestone. It gained 1.78% to complete the last trading session at $0.79.

What milestone has ARAV reached?

Aravive (ARAV) announced yesterday that its licensee, 3D Medicines Inc., has provided the company with a $6 million development milestone payment. As a result of the introduction of Aravive’s batiraxcept phase 3 clinical trial in China, this milestone has been reached.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


  • With the enrollment of batiraxcept (3D-299) in Phase 3 Trial in China, ARAV’s partnership with 3D Medicines is making positive progress.
  • In addition to supporting Aravive’s potential marketing application in the United States, its enrollment of patients will also support its potential marketing application in China.
  • In November 2020, ARAV entered into an agreement with 3D Medicines that marked its third milestone, and the company will continue to advance toward batiraxcept approval in both China and the United States.
  • 3D Medicines Inc. and Aravive have signed a collaboration and license agreement to develop and commercialize batiraxcept in oncology indications.
  • In accordance with the terms of the agreement, ARAV will receive milestone payments and royalties totaling up to $207 million.

Aravive achieved this $6 million development milestone in addition to receiving $9 million in development milestones related to batiraxcept’s development in the United States and China for platinum-resistant ovarian cancer, as well as $12 million upfront from 3D Medicines in 2020, for a total of $27 million.

ARAV participated in a major event:

On September 28, 2022, at the Lotte New York Palace Hotel, New York, N.Y., Aravive (ARAV) Chief Executive Officer Gail McIntyre, Ph.D., DABT, and Chief Financial Officer Rudy Howard attended the Cantor Fitzgerald Oncology & HemOnc Conference. A panel discussion with ARAV CEO on Wednesday, September 28, at 10:40 AM ET was titled “Companies with Key Catalysts Over the Next 12-18 Months.”